Question special
Lead Moderator

There have been recent debates regarding the interaction of academia, industry, and medical journals. There is also recent controversy regarding the extreme cost of some new therapies. Both of these ethical dilemas are relevant to CANTOS.

CANTOS was an industry sponsored trial that showed efficacy of an extremely expsive drug for a very common disease. Where do we go from here?